Luận án Nghiên cứu những yếu tố ảnh hưởng đến hiệu quả phân lập vi khuẩn kị khí và đặc điểm kháng kháng sinh của các chủng phân lập được tại bệnh viện hữu nghị việt đức (2015-2021)

oxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother, 45 (8), 2348-2353. 131. Gabriella Terhes, Jon S Brazier, József Sóki, et al. (2007). Coincidence of bft and cfiA genes in a multi-resistant clinical isolate of Bacteroides fragilis. Journal of medical microbiology, 56 (10), 1416-1418. 132. József Sóki, Zsuzsa Eitel, Edit Urbán, et al. (2012). Molecular analysis of the carbapenem and metronidazole resistance mechanisms of Bacteroides strains reported in a Europe-wide antibiotic resistance survey. Int J Antimicrob Agents, 41 (2), 122-125. 133. Fasahath Husain, Yaligara Veeranagouda, Justin Hsi, et al. (2013). Two multidrug-resistant clinical isolates of Bacteroides fragilis carry a novel metronidazole resistance nim gene (nimJ). Antimicrob Agents Chemother, 57 (8), 3767-3774. 134. Sonja Löfmark, Charlotta Edlund, and Carl Erik Nord (2010). Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis, 50 (Sup 1), S16-S23. 135. S. A. Magiorakos1 A.P., Carey2 R.B., armeli3 Y., et al (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for cquired resistance. BACTERIOLOGY, Clin Microbiol Infect 2012; 18: 268–281, 136. Z. H. b. Edit U*, József S.,et György L. (2014). First Hungarian case of an infection caused by multidrug-resistant Bacteroides fragilis strain Anaerobe, 137. R. M. I. M. Lyudmila B* (2019). Multidrug resistance in anaerobes Furture Medicine, TÀI LIỆU THAM KHẢO 1. Carroll K. C., Pfaller M. A., Landry M. L., et al. (2019). Manual of clinical microbiology, Wiley, New York, 1, 921-995. 2. Yi-Wei T., Max S., Dongyou L., et al. (2015). Molecular Medical Microbiology, Academic Press, Cambridge-Massachusetts. 3. Ryan K. J., Ray C. G., Nafees A., et al. (2010). Sherris medical microbiology, McGraw-Hill, New York, 6, 326-349. 4. Mahon C. R., Lehman D. C., and Manuselis G. et al.. (2015). Textbook of Diagnostic Microbiology Saunders, 5th Ed, Philadelphia, 495. 5. Patricia M. T. (2014). Bailey & Scott’s Diagnostic Microbiology, 13th Ed, Elsevier B.V, St. Louis, Missouri, 458-483. 6. Bartlett J. G, Sullivan-Sigler N., Louie T. J., et al (1976). Anaerobes survive in clinical specimens despite delayed processing. Journal of clinical microbiology, 3 (2), 133-136. 7. Asif N. and Shailesh K. (2022). Anaerobic Infections, StatPearl, Florida. 8. Brooks G. F., Karen C. C., Janet S., et al. (2013). Jawetz Melnick & Adelberg's Medical Microbiology, 26th Ed, McGraw-Hill Education, New York City. 9. Lê Văn Phủng (2009). Vi khuẩn y học, Nhà xuất bản giáo dục Việt Nam, Hà Nội. 10. Louie T. J., Bartlett J.G., Tally F. P. , et al. (1976). Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med, 85 (4), 461-463. 11. Lê Thị Thiều Hoa (2003). Nghiên cứu vi khuẩn kị khí trong một số nhiễm khuẩn ngoại khoa tại Bệnh viện Việt Đức, Đề tài Nghiên cứu khoa học cấp Bộ. 12. Mehrdad M., Hamed M., and Mitra M. (2022). The role of anaerobic bacteria in the development and prevention of colorectal cancer: A review study. Anaerobe, 73, 102501. 13. John E. B., Raphael D. and Martin J. B. (2015). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Ed, Saunders, Philadelphia, section 4, 2736. 14. Lynne S., Garcia and Henry D. I. (2007). Clinical microbiology procedures handbook, Third Ed, Wiley, Hoboken, New Jersey, Vol 1(4), 4.0.1 - 4.12.6. 15. Lê Huy Chính (2007). Vi sinh vật y học, Nhà xuất bản y học, Hà Nội. 16. Piotr S., Khanh V. T., Juliette P., et al. (2022). The role of the microbiota in the management of intensive care patients. Ann Intensive Care, 12, 1-16. 17. Đặng Thị Thùy Dương, Bùi Thị Việt Hà và Vũ Thị Thu Hường (2016). So sánh ba phương pháp xét nghiệm chẩn đoán nhiễm trùng do Clostidium difficile tại Việt Nam: Miễn dịch phát hiện độc tố, nested PCR và nuôi cấy Clostridium difficile sinh độc tố. Tạp chí Y học dự phòng, 15 (188), 18-23. 18. Patrick R. M. (2007). Manual of clinical microbiology, ASM Press, Washington DC, Section 4, 862-932. 19. Wren M. (1980). Prolonged primary incubation in the isolation of anaerobic bacteria from clinical specimens. Journal of Medical Microbiology, 13 (2), 257-264. 20. Shenoy P. A., Vishwanath S., Gawda A. và cộng sự (2017). Anaerobic Bacteria in Clinical Specimens - Frequent, But a Neglected Lot: A Five Year Experience at a Tertiary Care Hospital. J Clin Diagn Res, 11 (7), Dc44-dc48. 21. Baron E. J. and Finegold S. M. (1990). Bailey & Scott’s Diagnostic Microbiology, 8th Ed, Mosby, St. Louis. 22. Sutter V. L. (1980). Wadsworth anaerobic bacteriology manual, Mosby, St. Louis, Missouri. 23. Daichi F., Hiroshi T., Asako D., et al. (2014). Comparison of two transport systems available in Japan (TERUMO kenkiporter II and BBL Port-A-Cul) for maintenance of aerobic and anaerobic bacteria. Journal of Infection and Chemotherapy, 20 (1), 26-29. 24. Thomas D., Deborah D. G., Daisy V. D., et al. (2018). Extensive evaluation of fastidious anaerobic bacteria recovery from the Copan eSwab® transport system. J Microbiol Methods, 144, 73-78. 25. Wilkins T. D. and Jimenez- U. F. (1975). Anaerobic specimen transport device. Journal of clinical microbiology, 2 (5), 441-447. 26. Brook I. (1989). Aerobic and anaerobic microbiology of biliary tract disease. J Clin Microbiol, 27 (10), 2373-2375. 27. Rosenblatt J. and Stewart P. (1975). Anaerobic bag culture method. Journal of clinical microbiology, 1 (6), 527-530. 28. Rosenblatt J., Fallon A. and Finegold S. M. (1973). Comparison of methods for isolation of anaerobic bacteria from clinical specimens. Applied microbiology, 25 (1), 77-85. 29. Martin W.J. (1971). Practical method for isolation of anaerobic bacteria in the clinical laboratory. Applied microbiology, 22 (6), 1168-1171. 30. Wren M. (1977). The culture of clinical specimens for anaerobic bacteria: a comparison of three regimens. Journal of Medical Microbiology, 10 (2), 195-201. 31. Wren M., Baldwin A, Eldon C. P., et al (1977). The anaerobic culture of clinical specimens: a 14-month study. Journal of Medical Microbiology, 10 (1), 49-61. 32. Jean-C. L., Sophie E., Isabelle P., et al. (2015). Current and past strategies for bacterial culture in clinical microbiology. Clin Microbiol Rev, 28 (1), 208-236. 33. Julie D., Anna K., Jeremy H., et al. (1999). Evaluation of the Rapid ID 32A system for identification of anaerobic Gram-negative bacilli, excluding the Bacteroides fragilis group. Clin Microbiol Infect, 5 (6), 319-326. 34. Patrick R. M. (2017). Basic Medical Microbiology, 1st Ed, Amsterdam, 70-71. 35. Onder E., Demet E., Bulent K., et al. (2016). An unexpected tetanus case. Lancet Infect Dis, 16 (6), 746-752. 36. Nguyễn Văn Cường, Dương Thị Hồng (2016). Tình hình bệnh uốn ván sơ sinh ở Việt Nam giai đoạn 10 năm sau loại trừ bệnh uốn ván sơ sinh, 2006 – 2015. Tạp chí Y học dự phòng, 16 (4), 107-110. 37. Po-Chun C., Wen-Hao L., Yi-Chun C., et al. (2022). Oral Bacteria and Their Antibiotic Susceptibilities in Taiwanese Venomous Snakes. Microorganisms, 10 (5), 1-10. 38. Saied A., Frank D., Orla D., et al. (2022). Antimicrobial susceptibility patterns of anaerobic bacteria at an Irish University Hospital over a ten-year period (2010-2020). Anaerobe, 73, 102497. 39. Christopher A. D., Nicholas McG., Richard K., et al. (2020). Microbial aetiology of brain abscess in a UK cohort: Prominent role of Streptococcus intermedius. Observational Study J Infect, 80 (6), 623-629. 40. Seneviratne R de S., Navasivayam P, Perera S., et al. (2003). Microbiology of cerebral abscess at the neurosurgical unit of the National Hospital of Sri Lanka. Ceylon Medical Journal, 48 (1), 14-16. 41. Fernando C., Lina M.H, and José M .N (2022). Brain abscesses caused by anaerobic bacteria. Anaerobe, 76, 102614. 42. Murtaza M., Jayaram M., Rahman M. D. S., et al. (2014). Acute Biliary tract infections, Diagnostic criteria and Treatment. Int J Pharm Sci Invent, 3 (10), 58-62. 43. Gianfranco D., Emilio G., Roberta D. R., et al. (2007). Plastic biliary stent occlusion: factors involved and possible preventive approaches. Clinical Medicine & Research, 5 (1), 53-60. 44. Oyabu H., Tabata M., and Nakayama F. (1987). Nonbacterial transformation of bilirubin in bile. Digestive diseases and sciences, 32 (8), 809-816. 45. Tabata M. and Nakayama F. (1984). Bacteriology of hepatolithiasis. Progress in clinical and biological research, 152, 163-174. 46. Britta L., Daniel R. G., Christina M. W., et al. (2007). Reemergence of Anaerobic Bacteremia. Clinical infectious diseases, 44 (7), 895–900. 47. Yong-L. H., Qiao-L. S., Jia-P. L., et al. (2019). Evaluation of an in-house MALDI-TOF MS rapid diagnostic method for direct identification of micro-organisms from blood cultures. J Med Microbiol, 68 (1), 41-47. 48. Sharp S. E., McLaughlin J. C, Goodman J. M., et al. (1993). Clinical assessment of anaerobic isolates from blood cultures. Diagnostic microbiology and infectious disease, 17 (1), 19-22. 49. Rassolie A. and Özenci V. (2019). Short-term culture for rapid identification of anaerobic bacteria from blood cultures. Anaerobe, 57, 59-62. 50. Jan K., Valerie C., Jan B., et al. (2018). Diagnostic performance of blood culture bottles for vitreous culture compared to conventional microbiological cultures in patients with suspected endophthalmitis. Eur J Clin Microbiol Infect Dis, 37 (5), 889-895. 51. Tunney M. M., Field T. R, Moriarty T. F., et al. (2008). Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. American journal of respiratory and critical care medicine, 177 (9), 995-1001. 52. Kaori T., Hanh V., and Masahiro H (2021). In vitro activities and spectrum of lascufloxacin （KRP-AM1977) against anaerobes. Journal of Infection and Chemotherapy, 27 (8), 1265-1269. 53. Yen-T. L., Shao-H. W., Ming-L. L., et al. (2022). Microbiota dysbiosis in odontogenic rhinosinusitis and its association with anaerobic bacteria. Sci Rep, 12 (1), 21023. 54. Joanna C., Livia S. Z., and Karsten Z. (2022). Linking anaerobic gut bacteria and cardiovascular disease. Nat Microbiol, 7 (1), 14-15. 55. Spiegel C. A., Amsel R., Eschenbach D., et al. (1980). Anaerobic bacteria in nonspecific vaginitis. N Engl J Med, 303 (11), 601-607. 56. Legaria M. C., Barberis C., Famiglietti A., et al. (2022). Urinary tract infections caused by anaerobic bacteria. Utility of anaerobic urine culture. Anaerobe, 78, 102636. 57. Furuya- K. L., Clements A. C. A., Foster N. F., et al. (2017). Asymptomatic Clostridium difficile colonization in two Australian tertiary hospitals, 2012-2014: prospective, repeated cross-sectional study. Clin Microbiol Infect, 23 (1), 48.e41-48.e47. 58. Mitsutoshi S., Haru K., Hitoshi H., et al. (2019). Performance of laboratory tests for detection for Clostridioides difficile: A multicenter prospective study in Japan. Anaerobe, 60, 102107. 59. Brazier J., Chmelar D., Dubreuil L, et al. (2008). European surveillance study on antimicrobial susceptibility of Gram-positive anaerobic cocci. Int J Antimicrob Agents, 31 (4), 316-320. 60. Laura M. K., Caryn E. G., Peter C. A., et al (2004). Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother, 53 (6), 1039-1044. 61. David W. H. (2006). Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe, 12 (3), 115-121. 62. Pankuch G. A, Jacobs M. R., and Appelbaum P. C., (1993). Susceptibilities of 428 gram-positive and negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob Agents Chemother, 37 (8), 1649-1654. 63. Moubareck C., Gavini F., Vaugien L., et al. (2005). Antimicrobial susceptibility of Bifidobacteria. J Antimicrob Chemother, 55 (1), 38-44. 64. Bryskier A. (2001). Anti-anaerobic activity of antibacterial agents. Expert Opin Investig Drugs, 10 (2), 239-267. 65. Michael J. F., Alicia M., Kenneth E. A., et al (2004). Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis, 4, 5. 66. Liebetrau A., Rodloff A. C., Behra-Miellet J., et al. (2003). In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother, 47 (11), 3667-3671. 67. Finegold S. M, Molitoris D., and Väisänen M. L. (2009). Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother, 53 (1), 281-286. 68. Alexander C. J., Citron D. M., Brazier J. S., et al. (1995). Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens. J Clin Microbiol, 33 (12), 3209-3215. 69. David R. S., Nilda V. J., Laura A. McD., et al. (2010). Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis, 50 Suppl 1, S26-33. 70. Chia-Y. L., Yu-T. H., Chun-H. L., et al. (2008). Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother, 52 (9), 3161-3168. 71. Nagy E., Urbán E., and Carl E. N. (2011). Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect, 17 (3), 371-379. 72. James A. K., Andrew J. W., Heather J. A., et al. (2012). Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother, 56 (3), 1247-1252. 73. Ellie J. C. G., Diane M. C., Kerin L. T., et al. (2013). In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother, 57 (6), 2620-2630. 74. Noémi A. B., József S., Edit U., et al. (2011). Investigation of the prevalence of tetQ, tetX and tetX1 genes in Bacteroides strains with elevated tigecycline minimum inhibitory concentrations. Int J Antimicrob Agents, 38 (6), 522-525. 75. Nina H., Silje B. J., Hege S. T., et al. (2015). Anaerobic blood culture isolates in a Norwegian university hospital: identification by MALDI‐TOF MS vs 16S rRNA sequencing and antimicrobial susceptibility profiles. Apmis, 123 (9), 749-758. 76. Hammond J. M., Potgieter P. D., Hanslo D., et al (1995). The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. Chest, 108 (4), 937-941. 77. Kirtilaxmi K. B., Jyoti N., Shaila K., et al. (2014). Prevalence of extended spectrum beta-lactamase producing anaerobic bacteria in chronic periodontitis. Journal of Indian Society of Periodontology, 18 (5), 567-569. 78. Melo J. C., Raff M. J., Wunderlich H. F., et al. (1980). Metronidazole treatment of Bacteroides fragilis infections. The American journal of the medical sciences, 280 (3), 143-149. 79. Suata K., Watanabe K., Ueno K., et al. (1993). Antimicrobial susceptibility patterns and resistance transferability among Bacteroides fragilis group isolates from patients with appendicitis in Bali, Indonesia. Clinical infectious diseases, 16 (4), 561-566. 80. Arne C. R. (1991). Practical Anaerobic Bacteriology, ASM Press, Washington, Vol 5, Section 1. 81. Audrey N. S. (2014). Antimicrobial resistance and susceptibility testing of anaerobic bacteria. Clin Infect Dis, 59 (5), 698-705. 82. Holdeman L. V., Cato E. P., and Moore W. E. C. (1977). Anaerobe laboratory manual, 4th Ed, Anaerobe Laboratory, Virginia Polytechnic Institute and State University, Blacksburg. 83. Anshul S., Pallab R., and Archana A. (2022). Antimicrobial susceptibility testing of anaerobic bacteria: In routine and research. Anaerobe, 75, 102559. 84. Nagy E, Boyanova L., and Justesen U. S. (2018). How to isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories. Clin Microbiol Infect, 24 (11), 1139-1148. 85. Watt B. (1972). The recovery of clinically important anaerobes on solid media. J. rned. Microbiol.,, (5,211). 86. Watt B., and Collee J. G., (1974). Practical approaches to the isolation and identification of clinically important non-sporing anaerobes. In Infection with non-sporing anaerobic bacteria, edited by I. Phillips and M. Sussman. Livingstone: Edinburgh, 7. 87. Hollander H., Flodstrom A. and Holmberg K. (1975). Influence of the collection and transport of specimens on the recovery of bacteria from peritonsillar abscesses. J. elin. Microbiol., 2,504. 88. Sapala J. A., Ponka J. L. and Neblett T. R. (1975). The bacteriology of the biliary tract. In Anaerobic Henry Ford Hosp. med. J., 23,8 1. 89. Sutter L. V., and Finecold S. M. 1975. (1975). Wadsworth anaerobic bacteriology manual, University of California: Los Angeles. 90. Wolkins U. and Finecold S. M. (1975). Anaerobic specimen transport device. J. din. Microbiol., 2,441., (2,441.). 91. Watt B., Collee J. G. and Brown R. (1976). Tests of performance of anaerobic jars. J. clin. Path., 29,534. 92. Dowell V. R. (1974). Collection of specimens and primary isolation. Anaerobic bacteriaxde in disease. p 9. 93. Leber A. L. (2016). Clinical Microbiology Procedures Handbook. American Society for Microbiology; (4): 679-686., 94. Đoàn Quốc Hưng (2020). Phương pháp nghiên cứu trong Y sinh học, tập 1, Nhà xuất bản Y học, Hà Nội, 117-118. 95. Đặng Đức Hậu (2008). Xác suất thống kê, Nhà xuất bản giáo dục, Hà Nội, 162. 96. CLSI (2021). Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard; CLSI Document M11-A8; CLSI: Wayne, PA, USA. 97. EUCAST (2021). The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, version 7.1; European Committee for Antimicrobial Susceptibility Testing (EUCAST): Växjö, Sweden., 98. Kenneth R., George R. C., Nafees A., et al. (2014). Sherris Medical Microbiology, 6th Ed, McGraw-Hill Education, New York, Part 3, Chap 39, 515-534. 99. Wafaa J., Rotimi V. O (2014). Antimicrobial resistance among anaerobes isolated from clinical specimens in Kuwait hospitals: Comparative analysis of 11-year data Elsevier. 100. Wayne P. H. and Whelan J. G. (1983). Susceptibility testing of biliary bacteria obtained before bile duct manipulation. American Journal of Roentgenology, 140 (6), 1185-1188. 101. Marne C., Pallares R., Martin R., et al. (1986). Gangrenous cholecystitis and acute cholangitis associated with anaerobic bacteria in bile. European journal of clinical microbiology, 5 (1), 35-39. 102. Francesca T., Chiara T., Laura B., et al. (2016). The role of DNA amplification and cultural growth in complicated acute appendicitis. Pediatr Rep, 8 (3), 6487. 103. Lakshmi V., Rao R. R. and Dinakar I. (1993). Bacteriology of brain abscess–observations on 50 cases. Journal of Medical Microbiology, 38 (3), 187-190. 104. Ananth S. P., Vishwanath S., Targain R., et al (2016). Anaerobic infections in surgical wards: a two year study. Iran J Microbiol, 8 (3), 181-186. 105. Márió G., Gabriella S. and Edit U. (2017). Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik’s Cube of Clinical Microbiology. Antibiotics. 6, 25. 106. Wren M. (1980). Multiple selective media for the isolation of anaerobic bacteria from clinical specimens. Journal of clinical pathology, 33 (1), 61-65. 107. Heginbothom M., Fitzgerald T., Wade W. (1990). Comparison of solid media for cultivation of anaerobes. Journal of clinical pathology, 43 (3), 253-256. 108. Yamashita Y., Kohno S., Koga H., et al. (1994). Detection of Bacteroides fragilis in clinical specimens by PCR. Journal of clinical microbiology, 32 (3), 679-683. 109. Zargar N., Marashi M. A., Ashraf H., et al. (2019). Identification of microorganisms in persistent/secondary endodontic infections with respect to clinical and radiographic findings: bacterial culture and molecular detection. Iran J Microbiol, 11 (2), 120-128. 110. Vetor R., Murray C. K., Mende K., et al. (2016). The use of PCR/Electrospray Ionization-Time-of-Flight-Mass Spectrometry (PCR/ ESI-TOF-MS) to detect bacterial and fungal colonization in healthy military service members. BMC Infect Dis, 16, 338. 111. Tally F. P, Stewart P. R., Sutter V. L., et al. (1975). Oxygen tolerance of fresh clinical anaerobic bacteria. Journal of clinical microbiology, 1 (2), 161-164. 112. Gorbach S. L., Mayhew J. W., Bartlett J., et al. (1976). Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. The Journal of Clinical Investigation, 57 (2), 478-484. 113. Conny R. T., Dimas S. P., Ika N., et al. (2022). Distribution of anaerobic bacteria and their sensitivity pattern to several antibiotics at the clinical microbiology laboratory of school of medicine, universitas Indonesia, Jakarta in 2019-2020. Iran J Microbiol, 14 (1), 24-30. 114. McMinn M. T. and Crawford J. J. (1970). Recovery of anaerobic microorganisms from clinical specimens in prereduced media versus recovery by routine clinical laboratory methods. Applied microbiology, 19 (2), 207-213. 115. Stalons D. R., Thornsberry C. and Dowell V. (1974). Effect of culture medium and carbon dioxide concentration on growth of anaerobic bacteria commonly encountered in clinical specimens. Applied microbiology, 27 (6), 1098-1104. 116. Fatemeh R., Miseon P., and Rebecca W. (2005). Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi. Chemotherapy, 51 (5), 256-262. 117. Gwenaël L. M., Cédric L., Ghislaine G., et al. (2003). Characteristics of brain abscess with isolation of anaerobic bacteria. Scand J Infect Dis, 35 (5), 318-321. 118. Fernando Cobo (2022). Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria. Antibiotics (Basel), 11 (3), 351. 119. Schaumann R. P. S.., Fille M., Rodloff A. C. (2005). Inducible Metronidazole Resistance in nim-Positive and nim-Negative Bacteroides fragilis Group Strains after Several Passages on Metronidazole Containing Columbia Agar Plates. Infection. 33: 368–372. 120. Rotimi V., Khoursheed M., Brazier J., et al. (1999). Bacteroides species highly resistant to metronidazole: an emerging clinical problem? Clinical microbiology and infection, 5 (3), 166-169. 121. Brazier J. S., Hall V., Morris T. E., Gal M., et al. (2003). Antibiotic susceptibilities of Gram-positive anaerobic cocci: results of a sentinel study in England and Wales. J Antimicrob Chemother, 52 (2), 224-228. 122. Ho P. L., Ho L. Y., Yau C. Y., et al. (2017). A Novel Selective Medium for Isolation of Bacteroides fragilis from Clinical Specimens. J Clin Microbiol, 55 (2), 384-390. 123. Cristian M., Sunita P., Justin S., et al. (2016). Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An Emerging Challenge. Case Rep Infect Dis, 2016, 3607125. 124. Seyedesomaye J., Mohammad E., Zahra A., et al. (2021). Antibiotic resistance pattern of Bacteroides fragilis isolated from clinical and colorectal specimens. Ann Clin Microbiol Antimicrob, 20, 27. 125. Wareham D. W., Wilks M., Ahmed D., et al. (2005). Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy. Clin Infect Dis, 40 (7), e67-e68. 126. Alauzet C., Mory F., Teyssier C., et al. (2010). Metronidazole resistance in Prevotella spp and description of a new nim gene in Prevotella baroniae. Antimicrob Agents Chemother, 54 (1), 60-64. 127. Liliana F. C., Mirta L., María C. L., et al. (2012). First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina. Antimicrob Agents Chemother, 56 (3), 1309-1314. 128. Joseph P., Angeliki P., Anastasia K., et al. (2008). Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother, 62 (1), 137-141. 129. Ackermann G., Schaumann R., and Pless B. (2000). Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis, 19 (3), 228-232. 130. Ackermann G., Tang Y. J., Kueper R., et al. (2001). Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother, 45 (8), 2348-2353. 131. Gabriella T., Jon S. B., József S., et al. (2007). Coincidence of bft and cfiA genes in a multi-resistant clinical isolate of Bacteroides fragilis. Journal of medical microbiology, 56 (10), 1416-1418. 132. József S., Zsuzsa E., Edit U., et al. (2012). Molecular analysis of the carbapenem and metronidazole resistance mechanisms of Bacteroides strains reported in a Europe-wide antibiotic resistance survey. Int J Antimicrob Agents, 41 (2), 122-125. 133. Fasahath H., Yaligara V., Justin H., et al. (2013). Two multidrug-resistant clinical isolates of Bacteroides fragilis carry a novel metronidazole resistance nim gene (nimJ). Antimicrob Agents Chemother, 57 (8), 3767-3774. 134. Sonja L., Charlotta E., and Carl E. N. (2010). Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis, 50 (Sup 1), S16-S23. 135. Magiorakos S.A.,Carey A.P., armeli Y., et al. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for cquired resistance. Bacteriology, Clin Microbiol Infect 2012; 18: 268–281. 136. Edit U., Pharm D., Zoltán H., et al (2014). First Hungarian case of an infection caused by multidrug-resistant Bacteroides fragilis strain, Anaerobe. S1075-9964(14)00141-3. 137. Lyudmila B., Rumyana M. & Ivan M. (2019). Multidrug resistance in anaerobes, Furture Medicine. 14(12), 1055–1064. PHỤ LỤC Số:......................... PHIẾU ĐIỀU TRA Người điều tra: Nguyễn Thị Vân Địa điểm: Khoa Vi sinh- Bệnh viện HN Việt Đức Thời gian: ............................................................................................. I. Thông tin bệnh nhân Họ và tên: ........................................................ Tuổi: ........................................................ Giới: Nam □ Nữ□ Khoa, phòng: ........................................................ II. Loại bệnh phẩm Mủ Mủ áp xe não. □ . Số lượng mẫu: > 2ml □ , < 2ml □ (cụ thể:ml) Môi trường vận chuyển: xi lanh □ khác □............ Mủ xương và phần mềm. □ Số lượng mẫu: > 2ml □ , < 2ml □ (cụ thể:ml) Môi trường vận chuyển: xi lanh □ khác □............ Khác □..................................... Số lượng mẫu: > 2ml □ , < 2ml □ (cụ thể:ml) Môi trường vận chuyển: xi lanh □ khác □............ Dịch. Dịch ổ bụng □ . Số lượng mẫu: > 2ml □ , < 2ml □ (cụ thể:ml) Môi trường vận chuyển: xi lanh □ khác □............ Dịch mật. □ Số lượng mẫu: > 2ml □ , < 2ml □ (cụ thể:ml) Môi trường vận chuyển: xi lanh □ khác □............ Khác □..................................... Số lượng mẫu: > 2ml □ , < 2ml □ (cụ thể:ml) Môi trường vận chuyển: xi lanh □ khác □............ III.Thời gian: Thời gian lấy mẫu: ................................................................. Thời gian nhận bệnh phẩm: ................................................................. Thời gian trả kết quả 1: ................................................................. Thời gian trả kết quả 2: ................................................................. Thời gian trả kết quả 3: ................................................................. IV. Vận chuyển và nhận bệnh phẩm Người đưa bệnh phẩm: ................................................................. Người nhận bệnh phẩm: ................................................................. Người cấy bệnh phẩm: Huyên Người đọc bệnh phẩm: Vân- Hằng VI. Kết quả nuôi cấy ái khí Âm tính □ Dương tính □ Stt Vi sinh vật Tỉ lệ mọc Vk/ml Rất ít Ít Vừa Nhiều Quá nhiều 1 2 3 Kháng sinh vi sinh vật 1 2 3 Kháng sinh vi sinh vật 1 2 3 Kháng sinh vi sinh vật 1 2 3 Ampicillin Ertapenem Ciprofloxacin Amoxicillin+clavulanic Imipenem Doxycycline Ticarcillin+clavulanic Meropenem Co-trimoxazole Piperacillin+Tazobactam Gentamicin Colistin Oxacillin Amikacin Moxifloxacin Cefazolin Netilmicin Metronidazole Cefuroxime Vancomycin Clindamycin Cefotaxime Chloramphenicol Tigecycline Ceftriaxone Erythromycin Ceftazidime Tetracycline Cefoperazone+Sulbactam Levofloxacin Ghi chú: Rất ít: Vi khuẩn mọc 1 khuẩn lạc vùng 1 Ít: Vi khuẩn mọc ở vùng 1 có số lượng khuẩn lạc > 1 Vừa: Xuất hiện khuẩn lạc mọc ở vùng 2 Nhiều: Xuất hiện khuẩn lạc mọc ở vùng 3 Quá nhiều: Khuẩn lạc mọc dày cả 3 vùng trên đĩa thạch columbia VII. Kết quả nuôi cấy vi khuẩn kị khí Âm tính □ Dương tính □ Kháng sinh đồ của các chủng vi khuẩn kị khí: Vi sinh vật Kháng sinh 1 2 3 4 MIC Phiên giải MIC Phiên giải MIC Phiên giải MIC Phiên giải Amoxicillin+ Clavulanic Piperacillin+Tazobactam Meropenem Imipenem Ertapenem Metronidazole Moxifloxacin Clindamycin